Emosis, a medical device company specialising in cytomolecular diagnostics of hemostasis disorders, and 5-Diagnostics (5-D), a worldwide distributor for haemostasis products and in-vitro diagnostics (IVD), have signed an exclusive distribution agreement.

The agreement that covers at least 36 countries, Emosis has commenced commercialisation of the first Emo-test, HIT Confirm, in CE Mark-regulated countries.

HIT Confirm's performance, availability and user-friendliness make it a new generation of blood tests for confirming the diagnosis of a potentially lethal complication - heparin-induced thrombocytopenia (HIT) - of the most commonly used injectable anticoagulant worldwide, heparin.

"This agreement and the start of sales is a major leap forward for Emosis, after less than 30 months of operations!", said Frederic Allemand, CEO of Emosis. "HIT Confirm is the first of a series of cytomolecular blood tests being developed by Emosis, Emo-tests, which address largely unmet diagnosis or companion testing needs of hemostasis and thrombosis disorders; and HIT is the beachhead market from which we will build Emosis leadership in much larger markets."

5-Diagnostics said it is delighted to become the exclusive distributor for HIT Confirm. We are determined to bring innovation to the diagnostic technician and scientist by sourcing and manufacturing the very best research and clinical products available worldwide. Our commitment to high quality is reflected in our rapidly expanding portfolio of unique and specialised assays and components, and our collaboration with Emosis is a testament to this.

Financial terms of the agreement were not disclosed.